Illumina snares sequencing tech in $60M buyout

Illumina has struck a $60 million deal to enhance its genetic sequencing technology with the acquisition of Avantome. Avantome's owners will get $25 million of that upfront with the rest coming in contingency payments. And company founders Mostafa Ronaghi and Helmy Eltoukhy say they will take a place in Illumina's management team.

- read the AP story

Suggested Articles

CureVac named a permanent CEO, Franz-Werner Haas, and signed Novartis alum, Igor Splawski, Ph.D. as its new top scientist.

J&J studied the drug in midphase obesity clinical trials, but Merck sees it as a potential treatment for nonalcoholic steatohepatitis.

The Big Pharma paid $134 million to enter into the two partnerships but then dropped the projects after Voyager completed research activities.